Literature DB >> 27567554

Imaging after radiation therapy of thoracic tumors.

B Ghaye1, M Wanet2, M El Hajjam3.   

Abstract

Radiation-induced lung disease (RILD) is frequent after therapeutic irradiation of thoracic malignancies. Many technique-, treatment-, tumor- and patient-related factors influence the degree of injury sustained by the lung after irradiation. Based on the time interval after the completion of the treatment RILD presents as early and late features characterized by inflammatory and fibrotic changes, respectively. They are usually confined to the radiation port. Though the typical pattern of RILD is easily recognized after conventional two-dimensional radiation therapy (RT), RILD may present with atypical patterns after more recent types of three- or four-dimensional RT treatment. Three atypical patterns are reported: the modified conventional, the mass-like and the scar-like patterns. Knowledge of the various features and patterns of RILD is important for correct diagnosis and appropriate treatment. RILD should be differentiated from recurrent tumoral disease, infection and radiation-induced tumors. Due to RILD, the follow-up after RT may be difficult as response evaluation criteria in solid tumours (RECIST) criteria may be unreliable to assess tumor control particularly after stereotactic ablation RT (SABR). Long-term follow-up should be based on clinical examination and morphological and/or functional investigations including CT, PET-CT, pulmonary functional tests, MRI and PET-MRI.
Copyright © 2016. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Chest; Complication; Radiation therapy; Recurrence; Tumor

Mesh:

Year:  2016        PMID: 27567554     DOI: 10.1016/j.diii.2016.06.019

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  5 in total

Review 1.  Radiation-induced lung injury: current evidence.

Authors:  Marisol Arroyo-Hernández; Federico Maldonado; Francisco Lozano-Ruiz; Wendy Muñoz-Montaño; Mónica Nuñez-Baez; Oscar Arrieta
Journal:  BMC Pulm Med       Date:  2021-01-06       Impact factor: 3.317

Review 2.  Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review.

Authors:  Yuxuan Hao; Xiaoye Zhang; Li Yu
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

3.  Differential Diagnosis of COVID-19 Pneumonia in Cancer Patients Received Radiotherapy.

Authors:  Qi Zeng; Caihua Tang; Lisi Deng; Sheng Li; Jiani Liu; Siyang Wang; Hong Shan
Journal:  Int J Med Sci       Date:  2020-09-16       Impact factor: 3.738

4.  Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.

Authors:  Hidehito Horinouchi; Shinji Atagi; Satoshi Oizumi; Kadoaki Ohashi; Tomohiro Kato; Toshiyuki Kozuki; Masahiro Seike; Takashi Sone; Tomotaka Sobue; Takaaki Tokito; Hideyuki Harada; Tadashi Maeda; Tadashi Mio; Ikue Shirosaka; Kana Hattori; Eisei Shin; Haruyasu Murakami
Journal:  Cancer Med       Date:  2020-07-30       Impact factor: 4.452

5.  Group and Basis Restricted Non-Negative Matrix Factorization and Random Forest for Molecular Histotype Classification and Raman Biomarker Monitoring in Breast Cancer.

Authors:  Xinchen Deng; Kirsty Milligan; Ramie Ali-Adeeb; Phillip Shreeves; Alexandre Brolo; Julian J Lum; Jeffrey L Andrews; Andrew Jirasek
Journal:  Appl Spectrosc       Date:  2021-08-06       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.